AEON Biopharma, Inc. (AEON) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Company: AEON Biopharma, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) as a biosimilar to Botox® (onabotulinumtoxinA) for therapeutic indications. The company holds exclusive rights to commercialize ABP-450 in the U.S., Canada, EU, UK, and other territories.
Key Milestone: In January 2026, the FDA held a BPD Type 2a meeting regarding AEON's analytical similarity strategy. The FDA acknowledged scientific challenges but deemed AEON's analytical methodologies reasonable to support advancement toward a comprehensive analytical similarity package.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net (Loss) Income | $(39.2) million | $42.0 million |
| Operating Expenses | $12.8 million | $(73.0) million (Gain) |
| Cash and Cash Equivalents (Dec 31, 2025) | $3.0 million | $0.013 million |
| Accumulated Deficit | $(470.8) million | $(431.6) million |
| Convertible Notes (Fair Value) | $34.6 million | $11.7 million |
Note: 2024 net income was driven by a $100.8 million non-cash gain on the change in fair value of contingent consideration. 2025 results included a $75.6 million loss on issuance of warrants and a $22.9 million loss on the change in fair value of convertible notes.
Material Changes vs. Prior Period
- Operating Loss vs. Income: The company shifted from a reported operating income of $73.0 million in 2024 to an operating loss of $12.8 million in 2025. The 2024 income was primarily due to a $100.8 million gain on contingent consideration, whereas 2025 saw a $3.5 million gain in the same category.
- R&D Expenses: Decreased by 71% to $4.1 million in 2025 from $14.2 million in 2024, primarily due to the wind-down of Phase 2 clinical trials for migraine and cervical dystonia to pivot toward the biosimilar pathway.
- Financing Activity: The company raised approximately $18.3 million in a public offering (Jan 2025) and $6.0 million in a PIPE financing (Nov 2025/Jan 2026). It also exchanged $15.0 million in existing convertible notes with Daewoong for equity, a new $1.5 million convertible note, and warrants.
- Stock Split: A 1-for-72 reverse stock split was effected in February 2025.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. As of the filing date, cash is expected to fund operations only into the third quarter of 2026. Additional financing is required to continue development.
- Development Outlook: AEON plans to complete the majority of its analytical comparability program in 2026 and requests a BPD Type 2b meeting later in 2026. The company is not currently pursuing additional 351(a) indication-specific development programs.
- Listing Compliance: The company received a notice of non-compliance from NYSE American regarding stockholders' equity requirements. It has an 18-month compliance period to regain compliance by August 3, 2026, or face delisting.
- Legal Proceedings:
- Odeon Capital: Settled in October 2025 for $1.0 million cash, stock, and warrants (recorded $0.4 million gain).
- Aegis Capital: Lawsuit filed in November 2025 alleging failure to honor a right of first refusal (ROFR) during the PIPE financing. AEON filed a motion to dismiss in January 2026.
- Key Risks: Reliance on a single product candidate (ABP-450); dependence on Daewoong for manufacturing; uncertainty of FDA approval for a botulinum toxin biosimilar; and potential dilution from future equity financings.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.0 million cash balance against the burn rate to confirm the "third quarter 2026" funding estimate.
- FDA Feedback: Review the specific details of the FDA's feedback from the January 2026 BPD Type 2a meeting to assess the likelihood of avoiding additional clinical trials.
- Daewoong Relationship: Confirm the terms of the new $1.5 million convertible note and the "Termination Purchase Right" which allows Daewoong to buy AEON's know-how for $1.00 if AEON ceases commercialization efforts.
- Listing Status: Monitor progress on the NYSE American compliance plan to avoid delisting by August 2026.
- Legal Exposure: Track the status of the Aegis Capital lawsuit regarding the ROFR claim.